Positive HERIZON-GEA-01 Phase 3 Results Support Ziihera® as HER2-Targeted Agent-of-Choice and Ziihera Combination Regimens as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
Jazz Pharmaceuticals Showcases New Clinical and Translational Data for Modeyso in H3 K27M-mutant Diffuse Midline Glioma at SNO 2025
Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance
Jazz Pharmaceuticals Showcases Phase 4 Data Demonstrating Xywav® Oral Solution Treatment Effects and Real-World Evidence at World Sleep and Psych Congresses
Modeyso Included in National Comprehensive Cancer Network® Clinical Practice Guidelines in Oncology for H3 K27M-mutant Diffuse Glioma
Jazz Pharmaceuticals Enters Exclusive Licensing Agreement with Saniona to Develop and Commercialize SAN2355
E-Power Resources Inc. Announces Tetepisca Flake Graphite Property Delivers High-Value Concentrate Potential, Demonstrating High Recoveries and Premium Flake Size Distribution
